Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections

Pharmacotherapy

Volumn 18, Issue 1, 1998, Pages 175-183

  Messick, Chad R ^a   Mamdani, Muhammad ^d   McNicholl, Ian R ^a   Danziger, Larry H ^a,b   Rodvold, Keith A ^a,b   Condon, Robert E ^c   Walker, Alonzo P ^c   Edmiston Jr , Charles E ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; SULTAMICILLIN;

ABDOMINAL INFECTION; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST MINIMIZATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ABDOMINAL ABSCESS; ADULT; AMPICILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFOXITIN; CEPHAMYCINS; CLINICAL TRIALS; COST SAVINGS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; PENICILLINS; PERITONITIS; SULBACTAM; UNITED STATES;

EID: 0031964785     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. de Groot HGW, Hustinx PA, Lampe AS, Oosterwijk WM. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intraabdominal infections. J Antimicrob Chemother 1993;32:491-500.
2. Malangoni MA, Condon RE, Spiegel CA. Treatment of intraabdominal infections is appropriate with single-agent or combination antibiotic therapy. Surgery 1985;98:648-54.
3. Stone HH, Geheber CE, Kolb LD, Dunlop WE. Clinical comparison of cefotaxime versus the combination of gentamicin plus clindamycin in the treatment of peritonitis and similar polymicrobial soft-tissue surgical sepsis. Clin Ther 1981;4(suppl A):67-81.
4. Harding GKM, Buckwold FJ, Ronald AR, et al. Prospective, randomized comparative study of clindamycin, chloramphenicol and ticarcillin, each in combination with gentamicin, in therapy for intraabdominal and female genital tract sepsis. J Infect Dis 1980;142:384-93.
5. Eckhauser FE, Knol JA, Raper SE, Mulholland MW, Helzerman P. Efficacy of two comparative antibiotic regimens in the treatment of serious intraabdominal infections: results of a multicenter study. Clin Ther 1992;14:97-109.
6. Solomkin JS, Fant WK, Rivera JO, Alexander JW. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 1985;78(suppl 6A): 85-91.
7. Smith CR, Ambinder R, Lipsky JJ, et al. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections: a randomized double-blind trial. Ann Intern Med 1984;101: 469-77.
8. Polk HC, Fink MP, Laverdiere M, et al. Prospective, randomized study of piperacillin/tazobactam therapy of surgically treated intraabdominal infection. Am Surgeon 1993;59:598-605.
9. Baird I. Multicentered study of cefoperazone for treatment of intraabdominal infections and comparison of cefoperazone with cefamandole and clindamycin plus gentamicin for treatment of appendicitis and peritonitis. Rev Infect Dis 1983;5(suppl):S165-72.
10. Study Group of Intra-Abdominal Infections. A randomized controlled trial of ampicillin plus sulbactam vs. gentamicin plus clindamycin in the treatment of intraabdominal infections: a preliminary report. Rev Infect Dis 1986;8(suppl 5):S583-8.
11. Yellin AE, Heseltine PNR, Berne TV, et al. The role of Pscudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985;161:303-7.
12. Schentag JJ, Wels PB, Reitberg DP, Walczak P, Hawkins Van Tyle J, Lascola RJ. A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Ann Surg 1983;198:35-41.
13. Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a β-lactamase inhibitor combination for serious intraabdominal infection. Ann Surg 1993;217:115-21.
14. Johnstone DM, Kirking DM, Vinson BE. Comparison of adverse drug reactions detected by pharmacy and medical records departments. Am J Health-Syst Pharm 1995;52: 297-301.
15. DiPiro JT, Cue JI. Single-agent versus combination antibiotic therapy in the management of intraabdominal infections. Pharmacotherapy 1994;14:266-72.
16. Gill MA, Chenella FC, Yellin AE, et al. Antibiotic cost analysis in patients with abdominal stab wounds. Curr Ther Res 1985;38:931-8.
17. Kreter B. Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin + aminoglycoside combination therapy for treatment of serious lower respiratory, intraabdominal, gynecologic, and urinary tract infections. Clin Ther 1992;14:110-21.
18. Norrby SR, Eriksson M, Ottosson E. Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study. Scand J Infect Dis 1986;18:371-4.
19. Moore RD, Smith CR, Holloway JJ, Leitman PS. Cefotaxime vs. nafcillin and tobramycin for the treatment of serious infection: comparative cost-effectiveness. Arch Intern Med 1986;146:1153-7.
20. Pallares R, Pujol M, Pena C, et al. Cephalosporins as risk factor for nosocomial Enterococcus Faecalis bacteremia. Arch Intern Med 1993;153:1581-6.
21. Sonnenberg FA, Beck J. Markov models in medical decision making; a practical guide. Med Decis Making 1993;13:322-38.
22. Dao TD. Cost-benefit and cost-effectiveness analysis of drug therapy. Am J Hosp Pharm 1985;42:791-802.
23. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985;5:157-77.
24. Magnussen CR, Cave J. Nosocomial enterococcal infections: association with use of third-generation cephalosporin antibiotics. Am J Infect Control 1988;16:241-5.
25. Barrie PW, Christou NV, Dellinger EP, Rout WR, Stone HH, Waymack JP. Pathogenicity of enterococcus in surgical infections. Ann Surg 1990;212:155-9.
26. Condon RE, Krepel C, Edmiston CE Jr. Antibiotic resistance among intraabdominal pathogens. Infect Dis Clin Pract 1995;4(3 suppl):S150-5.
27. Nichols RL, Muzik AC. Enterococcal infections in surgical patients: the mystery continues. Clin Infect Dis 1992;15:72-6.
28. Eisenberg JM. Clinical economics; a guide to the economic analysis of clinical practices. JAMA 1989;262:2879-86.
29. Niinikoski J, Havia T, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intraabdominal infections. Surg Gynecol Obstet 1993;176:255-61.
30. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intraabdominal infections. Antimicrob Agents Chemother 1992;36:2766-73.